PATENT CLAIM ANALYSIS

Application Number: 16109585
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2020-01
Patent Classification: ["514", "169000"]

Abstract:
This invention provides new methods for a) identifying Cushing's Syndrome patients at high risk of developing hypokalemia during glucocorticoid receptor modulator (GRM) treatment, and b) for prophylactically treating such patients to prevent, or reduce the severity of, hypokalemia. Patients at such high risk may be identified prior to their developing hypokalemia. Such a patient may be an adult patient with endogenous Cushing's Syndrome having type 2 diabetes mellitus or glucose intolerance to control hyperglycemia secondary to hypercortisolism. Patients may be identified by an above-threshold level of ACTH or cortisol in a patient sample taken post-GRM administration or pre-GRM administration, respectively. Upon identifying such a patient prior to the development of low potassium, the present methods provide for prophylactically treating the patient by administration of one or more hypokalemia treatments concurrently with an increased dose of GRM or with an initial dose of GRM to prevent hypokalemia.

Claim (Index 9):
The method of  claim 3 , wherein the GRM is mifepristone.

Metadata:
- Claim Count in Document: 80.0
- Percentile: 96.0
- Lexical Diversity: 1.86207
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['16109561', '15627359', '15627414', '15565291', '15919719']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7880701540634604
- 35 USC 102 Novelty (BERT): 0.7507082706056818
- Combined Prediction Score: 0.7843339657176825
- Mean Citation Score: 471.483672
- Max Citation Score: 929.0943
- Similarity Product: 840.5051333310843

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test